Tissue Regenix appointed Drew Distin as vice president of its recently established subsidiary, Tissue Regenix Orthopaedic, North America.
Here are four notes:
1. Mr. Distin has held a number of senior sales and business development positions at Parkus Medical, Osiris Therapeutics, Nuortho Surgical, RTI Biologics and CryoLife.
2. The company's market strategy in the U.S. will focus on human tissue applications, initially starting with OrthoPure HT.
3. Tissue Regenix currently has ongoing clinical trials for the OrthoPure XM and OrthoPure XT products in Europe.
4. Mr. Distin will begin his new role on March 1.